Table 2.

Univariable analysis of cancer-specific and recurrence-free survivals (at 3-years of follow-up).

Factor	N	Dead	Cancer-specific survival	P value	N	Recurrence	Recurrence-free survival	P value
Gender
Female	19	10	52.1	0.265	15	11	33.3	0.013
Male	55	23	57.8		47	20	50.7
Age
<62 yrs	37	19	46.4	0.324	29	16	37.7	0.546
≥62 yrs	37	14	65.2		33	15	54.1
Location
Lip	7	1	83.3	0.491	7	1	83.3	0.383
Tongue	10	5	70		10	8	20
Floor of the mouth	24	10	61.3		20	8	63.3
Gingiva	5	2	60		4	2	50
Retromolar trigone	11	6	30.7		8	4	37.5
Hard palate	9	4	53.3		7	4	42.9
Buccal mucosa	8	5	37.5		6	4	33.3
Tumor size
T1	13	1	88.9	<0.001	13	4	83.3	0.009
T2	29	9	70.4		28	12	53.4
T3	9	5	30.5		8	5	30
T4	23	18	16.9		13	10	23.1
N status
0	41	11	76.9	0.003	37	13	63.5	0.006
1	12	7	17.8		10	7	18
2	17	13	24.2		13	10	15.4
3	4	2	50		2	1	50
Stage
I	12	1	88.9	<0.001	12	4	71.6	0.009
II	23	6	77.4		22	8	60
III	10	5	33.3		9	5	34.6
IV	29	21	26.9		19	14	23.7
Tumor grade
G1	42	13	67.8	0.037	36	15	55.7	0.195
G2/G3	32	20	42.1		26	16	35.3
Treatment modality
SG	28	28	76.2	0.050	26	10	55.2	0.134
SG + RT	23	23	47.7		21	13	32.8
CT + SG or RCT	23	23	37.8		15	8	50
Margin status*
Free of tumor	33	9	79.7	0.157	31	9	68.4	0.003
With tumor	24	11	50.1		23	16	26.1
Perineural permeation
Absent	66	28	58.2	0.243	54	25	49.8	0.041
Present	8	5	37.5		8	6	25
Lymphatic invasion
Absent	58	27	55.1	0.849	47	24	46.5	0.824
Present	16	6	61.1		15	7	53.3
EMMPRIN expression
0, 1+, 2+	18	3	88.5	0.011	17	8	58.8	0.882
3+ (overexpression)	58	30	45.7		45	23	43.3
EMMPRIN distribution
Homogeneous	45	18	59.2	0.503	37	18	50.5	0.898
Heterogeneous (periphery)	29	15	50.7		25	13	39.6
EMMPRIN fibroblasts
Absent	9	6	20.8	0.092	8	6	18.8	0.088
Present	65	27	60.1		54	25	50.6
Ki-67
<50% (low expression)	36	12	69.4	0.111	32	14	56.2	0.560
≥50% (high expression)	38	11	45		30	17	39.7

SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.

*Not determined in the 17 cases.